These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31106974)

  • 21. Immunological mechanisms and clinical implications of regulatory T cell deficiency in a systemic autoimmune disorder: roles of IL-2 versus IL-15.
    Yang CH; Tian L; Ling GS; Trendell-Smith NJ; Ma L; Lo CK; Stott DI; Liew FY; Huang FP
    Eur J Immunol; 2008 Jun; 38(6):1664-76. PubMed ID: 18465774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of BET protein BRD4 delays murine lupus.
    Wei S; Sun Y; Sha H
    Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
    Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
    Suárez-Fueyo A; Rojas JM; Cariaga AE; García E; Steiner BH; Barber DF; Puri KD; Carrera AC
    J Immunol; 2014 Jul; 193(2):544-54. PubMed ID: 24935930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of autoreactive T cells that help nucleobindin-injected mice produce anti-DNA antibodies.
    Kubota T; Watanabe N; Kaneko T; Satake F; Miura K; Kurosawa Y; Miyasaka N; Kanai Y
    Immunol Lett; 2001 Jan; 75(2):111-5. PubMed ID: 11137134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
    Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
    Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.
    Shimp SK; Chafin CB; Regna NL; Hammond SE; Read MA; Caudell DL; Rylander M; Reilly CM
    Cell Mol Immunol; 2012 May; 9(3):255-66. PubMed ID: 22543833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.
    Rodgers DT; McGrath MA; Pineda MA; Al-Riyami L; Rzepecka J; Lumb F; Harnett W; Harnett MM
    Arthritis Rheumatol; 2015 Apr; 67(4):1023-35. PubMed ID: 25546822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L; Chen HP; Ma Q
    Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
    Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
    Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
    Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium signaling in systemic lupus erythematosus T cells: a treatment target.
    Kyttaris VC; Zhang Z; Kampagianni O; Tsokos GC
    Arthritis Rheum; 2011 Jul; 63(7):2058-66. PubMed ID: 21437870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
    Zhang X; Wang G; Bi Y; Jiang Z; Wang X
    Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL/lpr mouse autoimmune model.
    Sharma J; Collins TD; Roach T; Mishra S; Lam BK; Mohamed ZS; Veal AE; Polk TB; Jones A; Cornaby C; Haider MI; Zeumer-Spataro L; Johnson HM; Morel LM; Larkin J
    Sci Rep; 2021 Mar; 11(1):6354. PubMed ID: 33737712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells.
    Mandik-Nayak L; Seo SJ; Sokol C; Potts KM; Bui A; Erikson J
    J Exp Med; 1999 Jun; 189(11):1799-814. PubMed ID: 10359584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
    Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
    J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.
    Yasuda K; Watkins AA; Kochar GS; Wilson GE; Laskow B; Richez C; Bonegio RG; Rifkin IR
    PLoS One; 2014; 9(7):e103478. PubMed ID: 25076492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.